A systematic pipeline of protein structure selection for computer-aided drug discovery: A case study on T790M/L858R mutant EGFR structures

被引:1
|
作者
Das, Agneesh Pratim [1 ,2 ]
Nandekar, Prajwal [3 ]
Mathur, Puniti [2 ]
Agarwal, Subhash M. [1 ,4 ]
机构
[1] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, Noida, Uttar Pradesh, India
[2] Amity Univ Uttar Pradesh, Amity Inst Biotechnol, Noida, Uttar Pradesh, India
[3] Schrodinger India Pvt Ltd, Bengaluru, Karnataka, India
[4] ICMR Natl Inst Canc Prevent & Res, Bioinformat Div, I-7,Sect 39, Noida 201301, Uttar Pradesh, India
关键词
binding pose metadynamics; cross docking; drug discovery; EGFR; kinase; structure selection; virtual screening; NONCOVALENT INHIBITORS; RECEPTOR; DOCKING; RESISTANCE; BINDING;
D O I
10.1002/pro.4740
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Virtual screening (VS) is a routine method to evaluate chemical libraries for lead identification. Therefore, the selection of appropriate protein structures for VS is an essential prerequisite to identify true actives during docking. But the presence of several crystal structures of the same protein makes it difficult to select one or few structures rationally for screening. Therefore, a computational prioritization protocol has been developed for shortlisting crystal structures that identify true active molecules with better efficiency. As identification of small-molecule inhibitors is an important clinical requirement for the T790M/L858R (TMLR) EGFR mutant, it has been selected as a case study. The approach involves cross-docking of 21 co-crystal ligands with all the structures of the same protein to select structures that dock non-native ligands with lower RMSD. The cross docking performance was then correlated with ligand similarity and binding-site conformational similarity. Eventually, structures were shortlisted by integrating cross-docking performance, and ligand and binding-site similarity. Thereafter, binding pose metadynamics was employed to identify structures having stable co-crystal ligands in their respective binding pockets. Finally, different enrichment metrics like BEDROC, RIE, AUAC, and EF1% were evaluated leading to the identification of five TMLR structures (5HCX, 5CAN, 5CAP, 5CAS, and 5CAO). These structures docked a number of non-native ligands with low RMSD, contain structurally dissimilar ligands, have conformationally dissimilar binding sites, harbor stable co-crystal ligands, and also identify true actives early. The present approach can be implemented for shortlisting protein targets of any other important therapeutic kinases.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Design and investigation of novel iridoid-based peptide conjugates for targeting EGFR and its mutants L858R and T790M/L858R/C797S: an in silico study
    Das, Amrita
    Biggs, Mary A.
    Hunt, Hannah L.
    Mahabadi, Vida
    Goncalves, Beatriz G.
    Phan, Chau Anh N.
    Banerjee, Ipsita A.
    MOLECULAR DIVERSITY, 2024, : 2517 - 2541
  • [22] Computational identification of natural product inhibitors against EGFR double mutant (T790M/L858R) by integrating ADMET, machine learning, molecular docking and a dynamics approach
    Agarwal, Subhash M.
    Nandekar, Prajwal
    Saini, Ravi
    RSC ADVANCES, 2022, 12 (26) : 16779 - 16789
  • [23] Psorachromene induces apoptosis and suppresses tumor growth in NSCLC cells harboring EGFR L858R/T790M/C797S
    Wang, Tong-Hong
    Leu, Yann-Lii
    Chen, Chin-Chuan
    Li, Hsin-Jung
    Yang, Shuenn-Chen
    Huang, Kuo-Yen
    Chen, Chi-Yuan
    PHYTOTHERAPY RESEARCH, 2022, 36 (05) : 2116 - 2126
  • [24] Deciphering the molecular mechanism of enhanced tumor activity of the EGFR variant T790M/L858R using melanoma cell lines
    Shao, Hanshuang
    Wells, Alan
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [25] Safety and Efficacy of Osimertinib in the Treatment of a Patient With Metastatic Lung Cancer and Concurrent Somatic EGFR L858R and Germline EGFR T790M Mutations
    Ma, Weijie
    Gong, Jay
    Shan, Jidong
    Lewis, Debbie
    Xiao, Wenwu
    Moore, Elizabeth H.
    Zhang, Yanhong
    Hung, Jamie
    Mans, Nicole Z.
    Wei, Sixi
    Welborn, Jenna
    Stollenwerk, Nicholas S.
    Lam, Kit S.
    Li, Tianhong
    JCO PRECISION ONCOLOGY, 2018, 2 : 1 - 7
  • [26] Fused in silico and bioactivity evaluation method for drug discovery: T001-10027877 was identified as an antiproliferative agent that targets EGFRT790M/C797S/L858R and EGFRT790M/L858R
    Wang, Linxiao
    Huang, Xiaoling
    Xu, Shidi
    An, Yufeng
    Lv, Xinya
    Zhu, Wufu
    Xu, Shan
    Tu, Yuanbiao
    Chen, Shuhui
    Lv, Qiaoli
    Zheng, Pengwu
    BMC CHEMISTRY, 2024, 18 (01)
  • [27] De Novo T790M Mutation in an L858R Epidermal Growth Factor Receptor Mutant-Associated Lung Adenocarcinoma
    Fujiwara, Takumi
    Kobayashi, Tetsu
    Yasuma, Taro
    D'Alessandro-Gabazza, Corina N.
    Toda, Masaaki
    Fujimoto, Hajime
    Fujiwara, Kentaro
    Takeshita, Atsuro
    Nishihama, Kota
    Okano, Tomohito
    D'Alessandro, Valeria Fridman
    Takei, Yoshiyuki
    Hataji, Osamu
    Gabazza, Esteban C.
    CANCERS, 2020, 12 (10) : 1 - 13
  • [28] Design, synthesis and biological evaluation of new series of hexahydroquinoline and fused quinoline derivatives as potent inhibitors of wild-type EGFR and mutant EGFR (L858R and T790M)
    Shaheen, Mennatallah A.
    El-Emam, Ali A.
    El-Gohary, Nadia S.
    BIOORGANIC CHEMISTRY, 2020, 105
  • [29] Discovery of N-aryl-N'-pyrimidin-4-yl ureas as irreversible L858R/T790M mutant selective epidermal growth factor receptor inhibitors
    Zhou, Fusheng
    Zhang, Liang
    Jin, Yunzhou
    Liu, Wei
    Cheng, Pengfei
    He, Xiangyu
    Xie, Jing
    Shen, Sida
    Lei, Jing
    Ji, Haixia
    Hu, Yi
    Liu, Yingtao
    Cui, Yumin
    Lv, Qiang
    Lan, Jiong
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2018, 28 (07) : 1257 - 1261
  • [30] Discovery of selective EGFR modulator to inhibit L858R/T790M double mutants bearing a N-9-Diphenyl-9H-purin-2-amine scaffold
    Hu, Jinxing
    Han, Yufei
    Wang, Jingtao
    Liu, Yue
    Zhao, Yanfang
    Liu, Yajing
    Gong, Ping
    BIOORGANIC & MEDICINAL CHEMISTRY, 2018, 26 (08) : 1810 - 1822